Summary
Thermo Fisher Scientific Inc. (TMO) announced a significant change in its board composition with the election of Judy C. Lewent as a director, effective May 27, 2008. Ms. Lewent brings extensive financial and executive leadership experience, having previously served as executive vice president and chief financial officer of Merck & Co., Inc. for a substantial period. Her appointment to the Strategy Review Committee further indicates the company's intent to leverage her expertise in shaping its strategic direction.
Key Highlights
- 1Judy C. Lewent was elected as a new director to the Board of Directors on May 27, 2008.
- 2Ms. Lewent was appointed to the Strategy Review Committee.
- 3Ms. Lewent possesses a strong financial background, having been EVP and CFO of Merck & Co., Inc. from 1980 to 2007.
- 4Her prior experience at Merck also includes a role as President, Human Health Asia.
- 5This filing pertains to Item 5.02 of the 8-K, covering director and officer changes.
- 6The event date of the board vote was May 26, 2008.
Frequently Asked Questions
Judy C. Lewent has been elected as a new director to the Board of Directors of Thermo Fisher Scientific Inc.
Ms. Lewent has been appointed to the Strategy Review Committee.
Ms. Lewent has a significant financial background, having served as the executive vice president and chief financial officer of Merck & Co., Inc. from 1980 to 2007. She also held the position of President, Human Health Asia at Merck.
This is a Current Report on Form 8-K, filed to report significant events that are of interest to investors. In this case, the primary purpose is to announce the election of a new director and her committee appointment.